Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

References

• National Institute for Health and Care Excellence (NICE) . Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. (2019).
   Google Scholar
• Chen S , ParmigianiG. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol.25(10), 1329–1333 (2007).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN) . Breast, Ovarian and Pancreatic Cancer. Genetic/Familial High Risk Assessment (2023).
   Google Scholar
• Paluch-Shimon S , CardosoF , SessaCet al. Prevention and screening in BRCA mutation carriers and mother breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol.27(Suppl. 5), v103–v110 (2016).
   PubMedGoogle Scholar
• Berg WA . How well does supplemental screening magnetic resonance imaging work in high-risk women?J. Clin. Oncol.32(21), 2193–2196 (2014).
   PubMed Web of Science ®Google Scholar
• Passaperuma K , WarnerE , CauserPAet al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br. J. Cancer107(1), 24–30 (2012).
   PubMed Web of Science ®Google Scholar
• Sessa C , BalmañaJ , BoberSLet al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann. Oncol.34(1), 33–47 (2023).
   PubMed Web of Science ®Google Scholar
• Mainiero MB , MoyL , BaronPet al. ACR appropriateness criteria® breast cancer screening. J. Am. Coll. Radiol.14(Suppl. 11), S383–S390 (2017).
   PubMedGoogle Scholar
• Li X , YouR , WangXet al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Clin. Cancer Res.22(15), 3971–3981 (2016).
   PubMed Web of Science ®Google Scholar
• Honold F , CamusM. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women’s BRCA carriers. Medwave.18(4), e7161 (2018).
   PubMedGoogle Scholar
• Jakub JW , PeledAW , GrayRJet al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA. Surg.153(2), 123–129 (2018).
   PubMed Web of Science ®Google Scholar
• Metcalfe K , GershmanS , GhadirianPet al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ.348, g226 (2014).
   PubMed Web of Science ®Google Scholar
• Heemskerk-Gerritsen BA , SeynaeveC , van AsperenCJet al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J. Natl Cancer Inst.107, djv033 (2015).
   PubMedGoogle Scholar
• King MC , WieandS , HaleKet al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA286(18), 2251–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Narod SA , BrunetJS , GhadirianPet al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet356(9245), 1876–1881 (2000).
   PubMed Web of Science ®Google Scholar
• Shafaee MN , Gutierrez-BarreraAM , LinHYet al. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. J. Clin. Oncol.33(Suppl. 28), 143–152 (2015).
   Web of Science ®Google Scholar
• Tentori L , GrazianiG. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res.52(1), 25–33 (2005).
   PubMed Web of Science ®Google Scholar
• Bryant HE , SchultzN , ThomasHDet al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature434(7035), 913–917 (2005). Erratum in: Nature. 447(7142), 346 (2007).
   PubMed Web of Science ®Google Scholar
• Farmer H , McCabeN , LordCJet al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Tutt A , RobsonM , GarberJEet al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet376(9737), 235–244 (2010).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration . FDA approves olaparib for germline BRCA-mutated metastatic breast cancer (2018). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer (Accessed 21September2020).
   Google Scholar
• AstraZeneca . Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer (2019). www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer-10042019.html (Accessed 21September2020).
   Google Scholar
• U.S. Food and Drug Administration . FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer (2018). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer (Accessed 21September2020).
   Google Scholar
• Pfizer . European Commission approves Talzenna (talazoparib) for patients with inherited (germline) BRCA-mutated locally advanced or metastatic breast cancer (2019). www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer (Accessed 21September2020).
   Google Scholar
• Tutt ANJ , GarberJE , KaufmanBet al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med.384(25), 2394–2405 (2021).
   PubMed Web of Science ®Google Scholar
• Litton JK , RugoHS , EttlJet al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N. Engl. J. Med.379(8), 753–763 (2018).
   PubMed Web of Science ®Google Scholar
• Robson ME , TungN , ContePet al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol.30(4), 558–566 (2019).
   PubMed Web of Science ®Google Scholar
• Litton JK , HurvitzSA , MinaLAet al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol.31(11), 1526–1535 (2020).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) . Breast Cancer. Clinical Practice Guidelines in Oncology-version 4.2022.
   Google Scholar
• Cardoso F , Paluch-ShimonS , SenkusEet al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol.31(9), 1145–1163 (2020).
   Google Scholar
• ClinicalTrials.gov. NCT03499353 NCT02282345.
   Google Scholar
• Odemis DA , CelikB , KilicErciyas Set al. Evaluation of BRCA1/2 gene mutations in patients with high-risk breast and/or ovarian cancer in Turkey. Turk. J. Biochem.47(1), 45–52 (2022).
   Google Scholar
• Geredeli C , YasarN , SakinA. Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population. Int. J. Breast Cancer.2019, 9645147 (2019).
   PubMed Web of Science ®Google Scholar
• Abeliovich D , KaduriL , LererIet al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet.60(3), 505–514 (1997).
   PubMed Web of Science ®Google Scholar
• Struewing JP , HartgeP , WacholderSet al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med.336(20), 1401–1408 (1997).
   PubMed Web of Science ®Google Scholar
• Bisgin A , SagSO , DoganMEet al. Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey. Breast.59, 24–32 (2022).
   Google Scholar
• Bahsi T , ErdemHB. Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: a single center study. Turk. J. Biochem.45(1), 83–90 (2020).
   Web of Science ®Google Scholar
• Kuchenbaecker KB , HopperJL , BarnesDRet al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA317(23), 2402–2416 (2017).
   PubMed Web of Science ®Google Scholar
• Tai Yu Chuan , DomchekSusan , ParmigianiGiovanniet al. Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers. J. Natl Cancer Inst.99(23), 1811–1814 (2007).
   PubMed Web of Science ®Google Scholar
• Ford D , EastonDF , StrattonMet al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet.62, 676–689 (1998).
   PubMed Web of Science ®Google Scholar
• Zhu Y , WuJ , ZhangCet al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget.7(43), 70113–70127 (2016).
   PubMedGoogle Scholar
• Copson ER , MaishmanTC , TapperWJet al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet. Oncol.19(2), 169–180 (2018).
   PubMed Web of Science ®Google Scholar
• Yoshida R . Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer.28(6), 1167–1180 (2021).
   PubMed Web of Science ®Google Scholar
• Engel C , FischerC. Breast cancer risks and risk prediction models. Breast Care (Basel).10(1), 7–12 (2015).
   PubMed Web of Science ®Google Scholar
• Daly MB , PalT , BerryMPet al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. (2021).
   Web of Science ®Google Scholar
• US Preventive Services Task Force, OwensDK , DavidsonKWet al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA322(7), 652–665 (2019).
   PubMed Web of Science ®Google Scholar
• Bisgin A , BogaI , YalavOet al. BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history. Breast J.25(5), 1029–1033 (2019).
   PubMed Web of Science ®Google Scholar
• Offitt K , GroegerE , TurnerS. The ’duty to warn’ a patient’s family members about hereditary disease risks. JAMA292, 1469–1473 (2004).
   PubMed Web of Science ®Google Scholar
• Linfield DT , RothbergMB , PfohERet al. Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system. Breast Cancer Res. Treat.195(2), 153–160 (2022).
   PubMed Web of Science ®Google Scholar
• Vande Perre P , ToledanoD , CorsiniCet al. Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: general practitioner and patient perspectives. Mol. Genet. Genomic Med.6(6), 957–965 (2018).
   PubMed Web of Science ®Google Scholar
• Seven M , BağcivanG , AkyuzAet al. Women with Family History of Breast Cancer: How Much Are They Aware of Their Risk? Cancer Educ. 33(4), 915–921 (2018).
   PubMed Web of Science ®Google Scholar
• Nycum G , AvardD , KnoppersBM. Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur. J. Hum. Gen.17(7), 872–880 (2009).
   PubMed Web of Science ®Google Scholar
• Lenoir N . UNESCO, genetics and human rights. Kennedy Inst. Ethics J.7(1), 31–42 (1997).
   PubMed Web of Science ®Google Scholar
• Dugan RB , WiesnerGL , JuengstETet al. Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience. Am. J. Med. Genet. Part C (Semin. Med. Genet).119C(1), 27–34 (2003).
   PubMed Web of Science ®Google Scholar
• Hudson K , HolohanMK , CollinsF. Keeping pace with the times–the Genetic Information Nondiscrimination Act of 2008. N. Engl. J. Med.358(25), 2661–2663 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor S , TreloarS , Barlow-StewartKet al. Investigating genetic discrimination in Australia: a large-scale survey of clinical genetics clients. Clin. Genet.68(1), 20–23 (2005).
   Google Scholar
• Nicolas P . Ethical and juridical issues of genetic testing. A review of the international regulation. Crit. Rev. Oncol. Hematol.69(1), 98–107 (2009).
   PubMedGoogle Scholar
• Ulusal Kanser Programı 2009–2015 . Ankara: T.C. Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı. Nisan (2009).
   Google Scholar
• Surbone A . Social and ethical implications of BRCA testing. Ann. Oncol.22(Suppl. 1), i60–i66 (2011).
   PubMedGoogle Scholar